Ancora Advisors’s ANI Pharmaceuticals ANIP Stock Holding History

Ancora Advisors’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-6	Closed	–	–	632
2016 Q4	$0	Buy	+6	New	+$367	﹤0.01%	1224

Other funds holding ANIP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ancora Advisors's ANIP Position: Q1 2017 in Review

Ancora Advisors sold out of ANI Pharmaceuticals (ANIP) in Q1 2017, closing a stake of 6 shares.

Ancora Advisors first reported a position in ANIP in Q4 2016 and held it in 1 quarter. The position peaked at $0 in Q4 2016. 158 funds tracked by Wall St. Rank hold ANIP as of Q1 2017.

Ancora Advisors reported no remaining ANI Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Ancora Advisors sold 6 ANI Pharmaceuticals shares in Q1 2017.
Ancora Advisors first reported a position in ANI Pharmaceuticals in Q4 2016 and held it in 1 quarter.
Ancora Advisors's ANI Pharmaceuticals position peaked at $0 in Q4 2016.
158 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2017.

Based on Ancora Advisors's 13F filing for Q1 2017, filed 15 May 2017.